Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers

Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Coulter, Jonathan B., Easwaran, Hariharan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Primer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138788/
https://www.ncbi.nlm.nih.gov/pubmed/37104249
http://dx.doi.org/10.1371/journal.pbio.3002081
_version_ 1785032789604696064
author Coulter, Jonathan B.
Easwaran, Hariharan
author_facet Coulter, Jonathan B.
Easwaran, Hariharan
author_sort Coulter, Jonathan B.
collection PubMed
description Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies.
format Online
Article
Text
id pubmed-10138788
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-101387882023-04-28 Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers Coulter, Jonathan B. Easwaran, Hariharan PLoS Biol Primer Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies. Public Library of Science 2023-04-27 /pmc/articles/PMC10138788/ /pubmed/37104249 http://dx.doi.org/10.1371/journal.pbio.3002081 Text en © 2023 Coulter, Easwaran https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Primer
Coulter, Jonathan B.
Easwaran, Hariharan
Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
title Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
title_full Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
title_fullStr Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
title_full_unstemmed Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
title_short Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers
title_sort combining ezh2 and hdac inhibitors to target castration-resistant prostate cancers
topic Primer
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138788/
https://www.ncbi.nlm.nih.gov/pubmed/37104249
http://dx.doi.org/10.1371/journal.pbio.3002081
work_keys_str_mv AT coulterjonathanb combiningezh2andhdacinhibitorstotargetcastrationresistantprostatecancers
AT easwaranhariharan combiningezh2andhdacinhibitorstotargetcastrationresistantprostatecancers

Ejemplares similares